PHARMACOGENOMICS ANALYSIS OF GENETIC VARIANTS INFLUENCING DRUG RESPONSE

Abstract

The objective of this study is to examine the role played by the genetic variants in the interindividual variability in response to drugs in a pharmacogenomic method. One hundred and eighty patients were recruited with diagnosis of [Disease] and on treatment with [Drug Name], 95 respondents were recruited and 85 non-responders. The genomic DNA was then isolated on the basis of peripheral blood samples and genotyped on the basis of selected polymorphism of important pharmacogenes (e.g., CYP2D6, CYP2C9, ABCB1) via PCR based methods and Sanger sequencing. The allele and genotype frequencies were derived and Hardy Weinberg equilibrium was ensured (p>0.05). Logistic regression established a statistical change in the drug response in the presence of the CYP2C9 variable, which associated the CYP2C9 variant allele as being significant specifically with a value of OR = 2.34 with a 95% CI: 1.453-78; p = 0.001).The relationship between the ABCB1 polymorphism exhibited a moderate correlation between the reduced drug efficacy (p = 0.012). Also, there was a 28 per cent greater incidence of adverse drug reaction in patients with the variant genotype than the individuals of the wild type. The independent contribution of these genetic variants to the treatment outcomes in multivariate analysis controlled by age, gender, and clinical variables proved the independent effect of these genetic variants (p < 0.05). Finally, the results suggest that certain pharmacogenomic patterns have a great impact on drug responses and safety, which indicates their possible application as predictors of personalised medicine and improved therapy plans.